Xinlong Ma

952 citations
27 papers · 768 indexed · h-index 14
Topics
Cancer-related molecular mechanisms research (10 papers)MicroRNA in disease regulation (7 papers)Cancer-related gene regulation (6 papers)
Partner nations
ChinaJapan

In The Last Decade

Xinlong Ma

27 papers receiving 763 citations

Peers

Xinlong Ma
Comparison fields: 5 of 83
  • Molecular Biology 555
  • Cancer Research 404
  • Oncology 93
  • Rheumatology 86
  • Pulmonary and Respiratory Medicine 67
Replace Pamela Swain with:
Pamela Swain United States
Mengjun Ma China
Lorraine Rose United Kingdom
Pinglin Lai China
Chaofei Yang China
Kwang-Youl Lee South Korea
Yuanxin Zhu China
Jianbo Fan China
Guoli Hu China
Xinlong Ma relative to Pamela Swain United States Pamela Swain's profile →
Citations per field
00.5×1.5×1.9×
Pamela Swain · 1×
Citations per year

Countries citing papers authored by Xinlong Ma

Since Specialization
Citations

This map shows the geographic impact of Xinlong Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xinlong Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xinlong Ma more than expected).

Fields of papers citing papers by Xinlong Ma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xinlong Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xinlong Ma. The network helps show where Xinlong Ma may publish in the future.

Co-authorship network of co-authors of Xinlong Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Xinlong Ma. A scholar is included among the top collaborators of Xinlong Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xinlong Ma. Xinlong Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 5
2 7
3 1
4 5
5 10
6 4
7 6
8 11
9 11
10 39
11 32
12 53
13 6
14 62
15 21
16 29
17
The Influence of Government Intervention on Logistics Enterprise's Adoption of Information Technology
3
18 60
19 29
20 156

About Xinlong Ma

Xinlong Ma is a scholar working on Cancer Research, Rheumatology and Molecular Biology, having authored 27 papers that have together received 768 indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (10 papers), MicroRNA in disease regulation (7 papers) and Cancer-related gene regulation (6 papers). The work is most often cited by research in Cancer Research (404 citations), Molecular Biology (555 citations) and Rheumatology (86 citations). Xinlong Ma has collaborated with scholars based in China and Japan. Frequent co-authors include Changbao Chen, Jianxiong Ma, Jianwei Lv, Fengbo Li, Zhihu Zhao, Xiaolei Sun, Toshiyuki Amano, Akira Nakamizo, Nobuhiro Hata and Masahiro Mizoguchi. Their work appears in journals such as PLoS ONE, Clinical Cancer Research and Biochemical and Biophysical Research Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026